Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Oral nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used in the treatment of pain in fibromyalgia, despite being considered not to be effective. OBJECTIVES: To assess the analgesic efficacy, tolerability (drop-out due to adverse events), and safety (serious adverse events) of oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults. SEARCH METHODS: We searched CENTRAL, MEDLINE, and Embase for randomised controlled trials from inception to January 2017. We also searched the reference lists of retrieved studies and reviews, and online clinical trial registries. SELECTION CRITERIA: We included randomised, double-blind trials of two weeks' duration or longer, comparing any oral NSAID with placebo or another active treatment for relief of pain in fibromyalgia, with subjective pain assessment by the participant. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data and assessed trial quality and potential bias. Primary outcomes were participants with substantial pain relief (at least 50% pain relief over baseline or very much improved on Patient Global Impression of Change scale (PGIC)) or moderate pain relief (at least 30% pain relief over baseline or much or very much improved on PGIC), serious adverse events, and withdrawals due to adverse events; secondary outcomes were adverse events, withdrawals due to lack of efficacy, and outcomes relating to sleep, fatigue, and quality of life. Where pooled analysis was possible, we used dichotomous data to calculate risk difference (RD) and number needed to treat for an additional beneficial outcome (NNT), using standard methods. We assessed the quality of the evidence using GRADE and created a 'Summary of findings' table. MAIN RESULTS: Our searches identified six randomised, double-blind studies involving 292 participants in suitably characterised fibromyalgia. The mean age of participants was between 39 and 50 years, and 89% to 100% were women. The initial pain intensity was around 7/10 on a 0 to 10 pain scale, indicating severe pain. NSAIDs tested were etoricoxib 90 mg daily, ibuprofen 2400 mg daily, naproxen 1000 mg daily, and tenoxicam 20 mg daily; 146 participants received NSAID and 146 placebo. The duration of treatment in the double-blind phase varied between three and eight weeks.Not all studies reported all the outcomes of interest. Analyses consistently showed no significant difference between NSAID and placebo: substantial benefit (at least 50% pain intensity reduction) (risk difference (RD) -0.07 (95% confidence interval (CI) -0.18 to 0.04) 2 studies, 146 participants; moderate benefit (at least 30% pain intensity reduction) (RD -0.04 (95% CI -0.16 to 0.08) 3 studies, 192 participants; withdrawals due to adverse events (RD 0.04 (95% CI -0.02 to 0.09) 4 studies, 230 participants; participants experiencing any adverse event (RD 0.08 (95% CI -0.03 to 0.19) 4 studies, 230 participants; all-cause withdrawals (RD 0.03 (95% CI -0.07 to 0.14) 3 studies, 192 participants. There were no serious adverse events or deaths. Although most studies had some measures of health-related quality of life, fibromyalgia impact, or other outcomes, none reported the outcomes beyond saying that there was no or little difference between the treatment groups.We downgraded evidence on all outcomes to very low quality, meaning that this research does not provide a reliable indication of the likely effect. The likelihood that the effect could be substantially different is very high. This is based on the small numbers of studies, participants, and events, as well as other deficiencies of reporting study quality allowing possible risks of bias. AUTHORS' CONCLUSIONS: There is only a modest amount of very low-quality evidence about the use of NSAIDs in fibromyalgia, and that comes from small, largely inadequate studies with potential risk of bias. That bias would normally be to increase the apparent benefits of NSAIDs, but no such benefits were seen. Consequently, NSAIDs cannot be regarded as useful for treating fibromyalgia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wolfe, F., Clauw, D. J., Fitzcharles, M., Goldenberg, D. L., Katz, R. S., Mease, P., Russell, A. S., Russell, I. J., Winfield, J. B., & Yunus, M. B. (2010) · Arthritis Care & Research · doi:10.1002/acr.20140 · Cited by 3,952
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471
Psychosomatic medicine in Germany: more timely than ever
Zipfel, S., Herzog, W., Kruse, J., & Henningsen, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447701 · Cited by 2,323
GRADE guidelines: 7. Rating the quality of evidence—inconsistency
Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., Alonso-Coello, P., Glasziou, P., Jaeschke, R., Akl, E. A., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.03.017 · Cited by 2,320
Fibromyalgia: A Clinical Review
Clauw, D. J. (2014) · JAMA · doi:10.1001/jama.2014.3266 · Cited by 1,674
WOLFE, F., CLAUW, D. J., FITZCHARLES, M.-A., GOLDENBERG, D. L., HÄUSER, W., KATZ, R. S., MEASE, P., RUSSELL, A. S., RUSSELL, I. J., & WINFIELD, J. B. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.100594 · Cited by 1,499
Self-citationMeta-Analysis in Clinical Research
L'ABBÉ, K. A., DETSKY, A. S., & O'ROURKE, K. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-224 · Cited by 1,267
Primary fibromyalgia (fibrositis): Clinical study of 50 patients with matched normal controls
Yunus, M., Masi, A. T., Calabro, J. J., Miller, K. A., & Feigenbaum, S. L. (1981) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(81)90096-2 · Cited by 910
An internet survey of 2,596 people with fibromyalgia
Bennett, R. M., Jones, J., Turk, D. C., Russell, I. J., & Matallana, L. (2007) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-8-27 · Cited by 865
GRADE guidelines: 12. Preparing Summary of Findings tables—binary outcomes
Guyatt, G. H., Oxman, A. D., Santesso, N., Helfand, M., Vist, G., Kunz, R., Brozek, J., Norris, S., Meerpohl, J., Djulbegovic, B., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.01.012 · Cited by 836
Worldwide epidemiology of fibromyalgia
Queiroz, L. P. (2013) · Current Pain and Headache Reports · doi:10.1007/s11916-013-0356-5 · Cited by 826
Guyatt, G., Oxman, A. D., Sultan, S., Brozek, J., Glasziou, P., Alonso-Coello, P., Atkins, D., Kunz, R., Montori, V., Jaeschke, R., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.01.006 · Cited by 762
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115.pub3 · Cited by 565
Self-citationInfluence of trial sample size on treatment effect estimates: meta-epidemiological study
Dechartres, A., Trinquart, L., Boutron, I., & Ravaud, P. (2013) · BMJ · doi:10.1136/bmj.f2304 · Cited by 544
Häuser, W., Ablin, J., Fitzcharles, M.-A., Littlejohn, G., Luciano, J. V., Usui, C., & Walitt, B. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.22 · Cited by 505
Self-citationSmall fibre pathology in patients with fibromyalgia syndrome
Üçeyler, N., Zeller, D., Kahn, A.-K., Kewenig, S., Kittel-Schneider, S., Schmid, A., Casanova-Molla, J., Reiners, K., & Sommer, C. (2013) · Brain · doi:10.1093/brain/awt053 · Cited by 498
Wolfe, F., Brähler, E., Hinz, A., & Häuser, W. (2013) · Arthritis Care & Research · doi:10.1002/acr.21931 · Cited by 443
Self-citationFitzcharles, M.-A., Ste-Marie, P. A., Goldenberg, D. L., Pereira, J. X., Abbey, S., Choinière, M., Ko, G., Moulin, D. E., Panopalis, P., Proulx, J., et al. (2013) · Pain Research and Management · doi:10.1155/2013/918216 · Cited by 409
Minimal Clinically Important Difference in the Fibromyalgia Impact Questionnaire
BENNETT, R. M., BUSHMAKIN, A. G., CAPPELLERI, J. C., ZLATEVA, G., & SADOSKY, A. B. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081090 · Cited by 407
Mansfield, K. E., Sim, J., Jordan, J. L., & Jordan, K. P. (2016) · Pain · doi:10.1097/j.pain.0000000000000314 · Cited by 402
“Evidence” in chronic pain–establishing best practice in the reporting of systematic reviews
Moore, A. R., Eccleston, C., Derry, S., Wiffen, P., Bell, R. F., Straube, S., & McQuay, H. (2010) · Pain · doi:10.1016/j.pain.2010.05.011 · Cited by 370
Self-citationPain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome
Moore, R. A., Straube, S., & Aldington, D. (2013) · Anaesthesia · doi:10.1111/anae.12148 · Cited by 362
Guidelines on the management of fibromyalgia syndrome – A systematic review
Häuser, W., Thieme, K., & Turk, D. C. (2010) · European Journal of Pain · doi:10.1016/j.ejpain.2009.01.006 · Cited by 347
Self-citationOaklander, A. L., Herzog, Z. D., Downs, H. M., & Klein, M. M. (2013) · Pain · doi:10.1016/j.pain.2013.06.001 · Cited by 312
Amitriptyline for neuropathic pain and fibromyalgia in adults
Moore, R. A., Derry, S., Aldington, D., Cole, P., & Wiffen, P. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008242.pub2 · Cited by 293
Self-citationMoore, R. A., Moore, O. A., Derry, S., Peloso, P. M., Gammaitoni, A. R., & Wang, H. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.107805 · Cited by 279
Self-citationFibromyalgia Syndrome Module at OMERACT 9: Domain Construct
MEASE, P., ARNOLD, L. M., CHOY, E. H., CLAUW, D. J., CROFFORD, L. J., GLASS, J. M., MARTIN, S. A., MOREA, J., SIMON, L., STRAND, C. V., et al. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090367 · Cited by 256
Häuser, W., Kosseva, M., Üceyler, N., Klose, P., & Sommer, C. (2011) · Arthritis Care & Research · doi:10.1002/acr.20328 · Cited by 244
Self-citationAssociation Between Analytic Strategy and Estimates of Treatment Outcomes in Meta-analyses
Dechartres, A., Altman, D. G., Trinquart, L., Boutron, I., & Ravaud, P. (2014) · JAMA · doi:10.1001/jama.2014.8166 · Cited by 233
Nüesch, E., Häuser, W., Bernardy, K., Barth, J., & Jüni, P. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201249 · Cited by 225
Self-citationReview of pharmacological therapies in fibromyalgia syndrome
Häuser, W., Walitt, B., Fitzcharles, M.-A., & Sommer, C. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4441 · Cited by 188
Self-citationHasnie, F. S., Breuer, J., Parker, S., Wallace, V., Blackbeard, J., Lever, I., Kinchington, P. R., Dickenson, A. H., Pheby, T., & Rice, A. S. C. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.11.029 · Cited by 144
Don’t middle your MIDs: regression to the mean shrinks estimates of minimally important differences
Fayers, P. M., & Hays, R. D. (2014) · Quality of Life Research · doi:10.1007/s11136-013-0443-4 · Cited by 95
Cited by
Nociplastic pain: towards an understanding of prevalent pain conditions
Fitzcharles, M.-A., Cohen, S. P., Clauw, D. J., Littlejohn, G., Usui, C., & Häuser, W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00392-5 · Cited by 1,253
Self-citationManagement of functional somatic syndromes and bodily distress
Henningsen, P., Zipfel, S., Sattel, H., & Creed, F. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000484413 · Cited by 335
Bair, M. J., & Krebs, E. E. (2020) · Annals of Internal Medicine · doi:10.7326/aitc202003030 · Cited by 298
Roenneberg, C., Sattel, H., Schaefert, R., Henningsen, P., & Hausteiner-Wiehle, C. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0553 · Cited by 111
Metadata
- Authors
- Derry, S., Wiffen, P. J., Häuser, W., Mücke, M., Tölle, T. R., Bell, R. F., & Moore, R. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-03-27
- Volume
- 2020
- Issue
- 2
- Pages
- CD012332-CD012332
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2509067244
- Cited by
- 71
- References
- 34
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.